Mosby's 2014 Nursing Drug Reference (303 page)

BOOK: Mosby's 2014 Nursing Drug Reference
11.64Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

oxazepam (Rx)

(ox-ay′ze-pam)

Func. class.:
Sedative/hypnotic; antianxiety

Chem. class.:
Benzodiazepine, short acting

 

Controlled Substance Schedule IV
ACTION:

Potentiates the actions of GABA, especially in the limbic system and the reticular formation

USES:

Anxiety, alcohol withdrawal, insomnia

CONTRAINDICATIONS:

Pregnancy (D), breastfeeding, children <6 yr, hypersensitivity to benzodiazepines, closed-angle glaucoma, psychosis

Precautions:
Geriatric patients, debilitated, renal/hepatic disease, depression, suicidal ideation, dementia, sleep apnea, seizure disorder

DOSAGE AND ROUTES
Calculator
Anxiety

• Adult:
PO
10-30 mg tid-qid, max 120 mg/day

• Geriatric:
PO
5 mg daily-bid initially, may increase, max 15 mg qid

Alcohol withdrawal

• Adult:
PO
15-30 mg tid-qid

Available forms:
Caps 10, 15, 30 mg

Administer:

• 
Without regard to food

SIDE EFFECTS

CNS:
Dizziness, drowsiness
, confusion, headache, anxiety, tremors, fatigue, depression, insomnia, hallucinations, paradoxical excitement, transient amnesia

CV:
Orthostatic hypotension
,
ECG changes, tachycardia,
hypotension

EENT:
Blurred vision
, tinnitus, mydriasis

GI:
Nausea, vomiting, anorexia

HEMA:
Leukopenia

INTEG:
Rash, dermatitis, itching

SYST:
Dependence

PHARMACOKINETICS

Peak 2-4 hr; metabolized by liver; excreted by kidneys; half-life 5-15 hr; crosses placenta, breast milk; protein binding 97%

INTERACTIONS

Increase:
oxazepam effects—CNS depressants, alcohol, disulfiram, oral contraceptives

Decrease:
oxazepam effects—oral contraceptives, phenytoin, theophylline, valproic acid

Decrease:
effects of levodopa

Drug/Herb

Increase:
CNS depression—kava, melatonin, valerian

Drug/Lab Test

Increase:
AST, ALT, serum bilirubin

Decrease:
WBC

NURSING CONSIDERATIONS
Assess:

• 
B/P (lying, standing), pulse; if systolic B/P drops 20 mm Hg, hold product, notify prescriber

 
Mental status: mood, sensorium, affect, sleeping pattern, drowsiness, dizziness,
suicidal thoughts/behaviors

 
Physical dependency, withdrawal symptoms:
headache, nausea, vomiting, muscle pain, weakness, tremors, seizures (long-term use)

Perform/provide:

• 
Assistance with ambulation during beginning therapy because drowsiness, dizziness occurs

• 
Safety measures, including side rails

Evaluate:

• 
Therapeutic response: decreased anxiety, restlessness, insomnia

Teach patient/family:

• 
That product may be taken without regard to food

• 
That medication not to be used for everyday stress or used >4 mo unless di
rected by prescriber; not to take more than prescribed dose because product may be habit forming

• 
To avoid OTC preparations (cough, cold, hay fever) unless approved by prescriber

• 
To avoid driving, activities that require alertness because drowsiness may occur

• 
To avoid alcohol, other psychotropic products unless directed by prescriber

• 
Not to discontinue product abruptly after long-term use

• 
To rise slowly because fainting may occur, especially among geriatric patients

• 
That drowsiness may worsen at beginning of treatment

• 
To notify prescriber if pregnancy is planned or suspected pregnancy (D)

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

OXcarbazepine (Rx)

(ox′kar-baz′uh-peen)

Trileptal

Func. class.:
Anticonvulsant

Chem. class.:
CarBAMazepine analog

ACTION:

May inhibit nerve impulses by limiting influx of sodium ions across cell membrane in motor cortex

USES:

Partial seizures

Unlabeled uses:
Trigeminal neuralgia, atypical panic disorder, bipolar disorder

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Pregnancy (C), breastfeeding, children <4 yr, hypersensitivity to carBAMazepine, renal disease, fluid restriction, hyponatremia, abrupt discontinuation, suicidal ideation

DOSAGE AND ROUTES
Calculator
Seizures, adjunctive therapy

• Adult:
PO
300 mg bid, may be increased by 600 mg/day in divided doses bid at weekly intervals; maintenance 1200 mg/day

• Child 4-16 yr:
PO
8-10 mg/kg/day divided bid; dose determined by weight, increase by 5 mg/kg/day q3days, max doses weight dependent

Conversion to monotherapy for partial seizures

• Adult:
PO
300 mg bid with reduction in other anticonvulsants; increase OXcarbazepine by 600 mg/day each week over 2-4 wk; withdraw other anticonvulsants over 3-6 wk; max 2400 mg/day

Initiation of monotherapy for partial seizures

• Adult:
PO
300 mg bid, increase by 300 mg/day q3days to 1200 mg in divided doses bid

Renal dose

• Adult:
PO
CCr <30 ml/min, 150 mg bid, increase slowly

Bipolar disorder/trigeminal neuralgia (unlabeled)

• Adult:
PO
300 mg bid, may increase by ≤600 mg/day

Available forms:
Film-coated tabs 150, 300, 600 mg; oral susp 300 mg/5 ml

Administer:
PO route

• 
Without regard to meals

• 
Oral susp:
shake well, use calibrated oral syringe provided, use or discard within 7 days of opening

SIDE EFFECTS

CNS:
Headache, dizziness, confusion, fatigue
, feeling abnormal, ataxia, abnormal gait, tremors, anxiety, agitation,
worsening of seizures, suicidal thoughts/behaviors

CV:
Hypotension
, chest pain, edema

EENT:
Blurred vision, diplopia, nystagmus
, rhinitis, sinusitis

GI:
Nausea, constipation, diarrhea
, anorexia, vomiting, abdominal pain, gastritis

INTEG:
Purpura, rash, acne

SYST:
Angioedema, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS)

PHARMACOKINETICS

PO:
Onset unknown; peak 4-6 hr; metabolized by liver to active metabolite; terminal half-life 7-9 hr metabolite; inhibits P450 CYP2C19, induces CYP3A4/5

INTERACTIONS

 
Contraindicated: MAOIs, ranolazine, nisoldipine

Increase:
CNS depression—alcohol

Decrease:
effects—felodipine, oral contraceptive, carBAMazepine

Decrease:
OXcarbazepine levels—carBAMazepine, PHENobarbital, phenytoin, valproic acid, verapamil

Drug/Herb

Increase:
anticonvulsant effect—ginkgo

Decrease:
anticonvulsant effect—ginseng, santonica

Drug/Lab Test

Decrease:
sodium

NURSING CONSIDERATIONS
Assess:

• 
Description of seizures: frequency, duration, aura

• 
Hyponatremia: headache, nausea, confusion, usually within the first 3 mo of treatment, but may occur ≤1 yr, if this product is being used with other products that decrease sodium, monitor sodium levels

• 
Electrolyte: sodium; T
4
; phenytoin (when given together)

 
Serious reactions:
angioedema, anaphylaxis, Stevens-Johnson syndrome

• 
CNS/mental status: mood, sensorium, affect, behavioral changes, confusion,
suicidal thoughts/behaviors;
if mental status changes, notify prescriber

• 
Eye problems: need for ophthalmic exams before, during, after treatment (slit lamp, funduscopy, tonometry)

• 
Pregnancy:
lack of seizure control due to MHD, a metabolite of OXcarbazepine, monitor seizure control

Perform/provide:

• 
Storage at room temp

Evaluate:

• 
Therapeutic response: decreased seizure activity

Teach patient/family:

• 
To avoid driving, other activities that require alertness

• 
To take twice a day at same intervals

• 
Not to discontinue medication quickly after long-term use, seizures may increase

• 
To inform prescriber if hypersensitive to carBAMazepine; multisystem hypersensitivity may occur, to report fever, other allergic symptoms

• 
To avoid use of alcohol while taking product

• 
To use alternative contraception if using hormonal method, to report if pregnancy is planned or suspected pregnancy (C)

• 
To report skin rashes immediately, serious skin reactions can occur

TREATMENT OF OVERDOSE:

Activated charcoal; give 0.9% NaCl (hypotensive state), atropine (bradycardia); use benzodiazepines, barbiturates for seizures

Other books

Dying for a Daiquiri by CindySample
His Christmas Virgin by Carole Mortimer
Flame Thrower by Alice Wade
The Arrangement by Bethany-Kris
Silver and Salt by Rob Thurman
Tara by Lesley Pearse
JR by HP